Adjuvant interferon in high-risk melanoma: The AIM HIGH study - United Kingdom Coordinating Committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma

Journal of Clinical Oncology

Volumn 22, Issue 1, 2004, Pages 53-61

  Hancock, B W ^a   Wheatley, K ^a   Harris, S ^a   Ives, N ^a   Harrison, G ^a   Horsman, J M ^a   Middleton, M R ^a   Thatcher, N ^a   Lorigan, P C ^a   Marsden, J R ^a   Burrows, L ^a   Gore, M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FATIGUE; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; LYMPH NODE; MAJOR CLINICAL STUDY; MELANOMA; MOOD DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM;

ADOLESCENT; ADULT; AFFECT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; RISK FACTORS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 3242686449     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.03.185     Document Type: Article

References (30)

1. Balch CM, Soong SJ, Gershwald JE, et al: Prognostic factors analysis of 17, 600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
2. Moliffe R, Hancock BW: Adjuvant therapy of malignant melanoma. Crit Rev Oncol Haematol 44:81-102, 2002
3. Kirkwood J, Hunt M. Smith T, et al: A randomised controlled trial of high dose interferon α2b for high risk melanoma. Proc Am Soc Clin Oncol 12:390, 1993 (abstr 1331)
4. Cascinelli N, Bufalino R, Morabito A, MacKie R: Results of adjuvant interferon study in WHO melanoma programme. Lancet 343:913-914, 1994
5. Kleeberg UR, Bröcker EB, Lejeune F, et al: Adjuvant trial in melanoma patients comparing rlFNα to IFNγ to Iscador to a control group after curative resection of high risk primary (>3mm) or regional lymph node metastasis (EORTC 18871). Eur J Cancer 35:582, 1999 (abstr 24)
6. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Co-operative Oncology Group. Am J Clin Oncol 5:649-655, 1982
7. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, et al: Randomized, surgical adjuvant clinical trial of recombinant Interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13:2776-2783, 1995
8. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Co-operative Oncology Group trial EST1684. J Clin Oncol 14:7-17, 1996
9. Kirkwood JM, Ibrahim J, Manola J: High-dose interferon versus GM2 vaccine in high-risk malignant melanoma. J Clin Oncol 19:4350, 2001
10. Pehamberger H, Soyer HP, Steiner A, et al: Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 16:1425-1429, 1998
11. Grob JJ, Dreno B, Salmoniere P, et al: Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. Lancet 351:1905-1910, 1998
12. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High and low-dose interferon alpha-2b in high risk melanoma: First analysis of Intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458, 2000
13. Eggermont AMM, Kleeberg UR, Ruiter DJ, et al. European Organisation for Research and Treatment of Cancer Melanoma Group trial experience with more than 2, 000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b, in American Society of Clinical Oncology Educational Book. Alexandria, VA, American Society of Clinical Oncology, 2001, pp 88-93
14. Cascinelli N, Belli F, MackKie RM, et al: Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet 358:866-869, 2001
15. Cameron DA, Cornbleet MC, Mackie RM, et al: Adjuvant interferon alpha 2b in high risk melanoma: The Scottish study. Br J Cancer 84:1146-1149, 2001
16. Hancock BW, Wheatley K, Harrison G, et al: Aim High-adjuvant interferon in melanoma (high risk): A United Kingdom Co-ordinating Committee on Cancer Res (UKCCCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma. Proc Am Soc Clin Oncol 20:349, 2001 (abstr 1393)
17. Kirkwood JM, Ibrahbim JG, Sosman JA, et al: High-dose Interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup Trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001
18. Kirkwood JM. Adjuvant therapy of high-risk resected melanoma: Relapse-free and overall survival effects of high-dose Interferon alpha-2b in randomised controlled multicenter trials E1684 and E2696 and Intergroup trials E1690 and E1694, in American Society of Clinical Oncology Educational Book. Alexandria, VA, American Society of Clinical Oncology, 2001, pp 94-101
19. Lens MB, Dawes M: Interferon alpha therapy for malignant melanoma: A systematic review of randomised controlled trials. J Clin Oncol 20:1818-1825, 2002
20. Wheatley K, Ives N, Hancock BW, et al: Does adjuvant interferon α for high risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241-252, 2003
21. Cole BF, Gelber RD, Kirkwood JM, et al: Quality-of-life adjusted survival analysis of Interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 14:2666-2673, 1996
22. Hillner BE, Kirkwood JM, Atkins MB, et al: Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based of projections from Eastern Co-operative Oncology Group 1684. J Clin Oncol 15:2351-2358, 1997
23. Gonzalez-Larriba JL, Serrano S, Alvarez-Mon M, et al: Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur J Cancer 36:2344-2352, 2000
24. Hancock BW, Dixon S, Turner LA, et al: AIM High: adjuvant interferon in melanoma (high risk) - The costs. Br J Cancer 86:27, 2002 (supp 1)
25. Hancock BW, Harris S, Wheatley K, et al: Adjuvant interferon-alpha in malignant melanoma: Current status. Cancer Treat Rev 26:81-89, 2000
26. Agarwala S. Melanoma and Sarcoma, in American Society of Clinical Oncolgy: ASCO Annual Meeting Summaries. Alexandria, VA, American Society of Clinical Oncolgy, 2001, pp 74-76
27. Eggermont AMM: The role interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer 37:2147-2153, 2001
28. Middleton MR, Thatcher N: Adjuvant interferon in melanoma: A resurrection?. Br J Cancer 84:1141-1142, 2001
29. Kirkwood JM, Ibrahim JG, Sondak VK, et al: Interferon alfa-2a for melanoma metastases. Lancet 359:978-979, 2002
30. Kefford RF. Adjuvant therapy of cutaneous melanoma: The interferon debate. Ann Oncol 14:358-365, 2003